HFS
ASND icon

Hantz Financial Services’s Ascendis Pharma A/S ASND Stock Holding History

Hantz Financial Services’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,328
Closed -$532K – 2467
2026
Q1 		$532K Buy
2,328
+1,087
+88% +$244K 0.01% 631
2025
Q4 		$265K Buy
1,241
+397
+47% +$82K ﹤0.01% 753
2025
Q3 		$168K Buy
844
+492
+140% +$91.8K ﹤0.01% 795
2025
Q2 		$61K Buy
352
+262
+291% +$42.7K ﹤0.01% 896
2025
Q1 		$14K Buy
+90
New +$12.9K ﹤0.01% 888

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Hantz Financial Services's ASND Position: Q2 2026 in Review

Hantz Financial Services sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 2,328 shares — an estimated $532K sold.

Hantz Financial Services first reported a position in ASND in Q1 2025 and held it in 5 quarters. The position peaked at $532K in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Hantz Financial Services reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Hantz Financial Services sold 2,328 Ascendis Pharma A/S shares in Q2 2026, an estimated $532K.
  • Hantz Financial Services first reported a position in Ascendis Pharma A/S in Q1 2025 and held it in 5 quarters.
  • Hantz Financial Services's Ascendis Pharma A/S position peaked at $532K in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.